

# Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists

Mahesh M Umapathysivam<sup>\*1,2,3,4</sup>, Elisa Araldi<sup>\*5,6,7</sup>, Benoit Hastoy<sup>1</sup>, Adem Y Dawed<sup>8†</sup>, Hasan Vatandaslar<sup>5</sup>, Shahana Sengupta<sup>1</sup>, Adrian Kaufmann<sup>5</sup>, Søren Thomsen<sup>1</sup>, Bolette Hartmann<sup>9</sup>, Anna E Jonsson<sup>10</sup>, Hasan Kabakci<sup>5</sup>, Swaraj Thaman<sup>11</sup>, Niels Grarup<sup>10</sup>, Christian T Have<sup>10</sup>, Kristine Færch<sup>9,10</sup>, Anette P Gjesing<sup>10</sup>, Sameena Nawaz<sup>1</sup>, Jane Cheeseman<sup>1,12</sup>, Matthew J Neville<sup>1,12</sup>, Oluf Pedersen<sup>13††</sup>, Mark Walker<sup>14</sup>, Christopher Jennison<sup>15</sup>, Andrew T Hattersley<sup>16</sup>, Torben Hansen<sup>13</sup>, Fredrik Karpe<sup>1,12</sup>, Jens J Holst<sup>9,13</sup>, Angus G Jones<sup>16</sup>, Michael Ristow<sup>5</sup>, Mark I McCarthy<sup>1,12,17^</sup>, Ewan R Pearson<sup>8</sup>, Markus Stoffel<sup>5,18#</sup>, Anna L Gloyn<sup>1,11,12,17,19#</sup>

1. Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK
2. Department of Endocrinology, Queen Elizabeth Hospital, SA Health, Australia
3. Southern Adelaide and Diabetes and Endocrinology Service, Bedford Park, Australia
4. NHRMC Centre of Clinical research Excellence in Nutritional Physiology, Interventions and outcomes University of Adelaide, South Australia, Australia
5. Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland
6. Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zürich, Switzerland,
7. Department of Cardiology and Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
8. Division of Population Health & Genomics, School of Medicine, University of Dundee, UK
9. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University Copenhagen, Denmark
10. Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark
11. Division of Endocrinology, Department of Pediatrics, Stanford School of Medicine, Stanford, USA
12. National Institute of Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Headington, Oxford, UK
13. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark
14. Translational and Clinical Research Institute, Newcastle University, UK
15. Department of Mathematics, University of Bath, UK
16. University of Exeter College of Medicine & Health, Exeter, UK
17. Wellcome Trust Centre for Human Genetics, University of Oxford, UK
18. Medical Faculty, University of Zürich, Zürich, Switzerland
19. Stanford Diabetes Research Centre, Stanford, USA

\*These authors contributed equally to the study

#These authors jointly supervised the study

†Current affiliation: Department of Genetics, Novo Nordisk Research Centre Oxford, Oxford, UK

††Center for Clinical Metabolic Research, Gentofte University Hospital, Copenhagen, Denmark

^ Current address: Genentech, 1 DNA Way, South San Francisco, CA 94080

## Corresponding Author:

Anna L. Gloyn DPhil

Department of Pediatrics, Division of Endocrinology & Diabetes, MC 5660, Stanford

School of Medicine, Centre for Academic Medicine, 453 Quarry Road, Palo Alto, CA

94304

[agloyn@stanford.edu](mailto:agloyn@stanford.edu)

51 **ABSTRACT**

52 Patients with type 2 diabetes vary in their response to currently available therapeutic  
53 agents (including GLP-1 receptor agonists) leading to suboptimal glycemic control  
54 and increased risk of complications. We show that human carriers of hypomorphic  
55 T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating  
56 monooxygenase (*PAM*), as well as *Pam*-knockout mice, display increased resistance  
57 to GLP-1 *in vivo*. *Pam* inactivation in mice leads to reduced gastric GLP-1R  
58 expression and faster gastric emptying: this persists during GLP-1R agonist  
59 treatment and is rescued when GLP-1R activity is antagonized, indicating resistance  
60 to GLP-1's gastric slowing properties. Meta-analysis of human data from studies  
61 examining GLP-1R agonist response (including RCTs) reveals a relative loss of 44%  
62 and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with  
63 hypomorphic *PAM* alleles p.S539W and p.D536G treated with GLP-1R agonist.  
64 Genetic variation in *PAM* has effects on incretin signaling that alters response to  
65 medication used commonly for treatment of T2D.

66

67 (Funded by the Wellcome, Medical Research Council, European Union, NIHR Oxford Biomedical  
68 Research Centre, United Kingdom, Registered on ClinicalTrials.gov, NCT02723110.)

69

70

71

72

## 73 **Summary Paragraph**

74 Type 2 diabetes (T2D) is a leading cause of morbidity and mortality globally<sup>1</sup>.  
75 Current management of T2D patients focuses on lowering glycemic exposure and  
76 reducing complications with lifestyle and pharmacological interventions<sup>2</sup>. Despite the  
77 availability of multiple medications to lower glycosylated hemoglobin (HbA1c), only 53%  
78 of individuals with T2D reach the glycemic target (HbA1c <7%)<sup>3, 4</sup>. There is potential  
79 to improve medication selection through “precision medicine” where patient specific  
80 factors (e.g. genetic markers) are used to indicate whether a patient is more or less  
81 likely to respond to a medication. Here we show that human carriers of hypomorphic  
82 T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating  
83 monooxygenase (*PAM*), as well as *Pam*-knockout mice, have reduced PAM enzyme  
84 activity, display increased resistance to glucagon like peptide 1 (GLP-1) *in vivo* and  
85 have reduced response to the GLP-1 receptor agonist. Meta-analysis of human data  
86 from studies examining GLP-1 receptor agonist response (including RCTs) reveals a  
87 relative loss of 44% and 20% of glucose lowering (measured by glycosylated  
88 hemoglobin) in individuals with hypomorphic *PAM* alleles p.S539W and p.D536G  
89 treated with GLP-1 receptor agonist. Genetic variation in *PAM* has effects on incretin  
90 signaling that alters response to medication used commonly for treatment of T2D.

## 91 **Main text**

92 Two independent loss of function coding alleles in *PAM* (p.S539W, rs78408340,  
93 minor allele frequency (MAF) ~1%, OR: 1.47 and p.D563G, rs35658696, MAF ~5%,  
94 OR: 1.23) increase T2D risk and reduce beta cell function<sup>5-7</sup>. The *PAM* gene  
95 encodes the PAM protein, which is the only enzyme capable of amidating the C-  
96 terminal glycine residue of certain peptides to an amide group, a post-translational  
97 mechanism necessary for full biological activity and stability of many hormones<sup>8, 9</sup>.

98 Several hormones known to regulate blood glucose concentration are amidated (e.g.  
99 gastrin, cholecystokinin and glucagon-like peptide 1(GLP-1))<sup>9-12</sup>. Aside from  
100 amidation, PAM also has several non-catalytic functions, including a role in  
101 intracellular protein trafficking<sup>7, 13</sup>. We have shown *in vitro* that PAM deficiency in  
102 human pancreatic beta cells causes reduced insulin content and altered dynamics of  
103 insulin secretion<sup>7</sup>. These experiments informed on the impact of PAM inactivation on  
104 beta-cell function in cell autonomous situations but were not able to assess whether  
105 PAM deficiency contributes to elevated diabetes risk by regulating other hormones  
106 affecting insulin secretion, gastric emptying or other metabolic pathways affected in  
107 diabetes. *PAM* knockdown in beta-cells altered the kinetics of exocytosis and the  
108 immediately available pool of insulin granules, this will reduce the effectiveness of  
109 GLP-1 in stimulating insulin secretion<sup>7</sup>. As a result, it is likely that, altered GLP-1  
110 response is a contributing factor to the diabetes risk phenotype observed in carriers  
111 of p.D563G and p.S539W<sup>7</sup>. GLP-1 is itself amidated by PAM and interacts with  
112 several other amidated peptides which regulate its secretion via multiple  
113 mechanisms<sup>14-16</sup>.

114 Altered GLP-1 plasma levels or GLP-1 sensitivity in carriers of *PAM* T2D risk alleles  
115 could have implications for the efficacy of two commonly prescribed medications for  
116 T2D: GLP-1R agonists (GLP-1RA) and dipeptidyl-peptidase 4 inhibitors (DPP-4i).  
117 Given that ≈10% of individuals carry a loss of function allele in the *PAM* gene,  
118 demonstration of GLP-1 deficit or resistance in carriers of *PAM* T2D risk alleles  
119 would impact the medication choice for many individuals with T2D<sup>5-7</sup>.

120 ***Amidation activity is reduced in carriers of PAM loss of function alleles and***  
121 ***Pam knockout in mice.***

122 First we confirmed that carriers of the *PAM* loss of function (LoF) alleles p.D536G  
123 (MAF~5%, presumed partial LoF) and p.S539W (MAF 1%, presumed complete LoF)  
124 have reduced *in vivo* *PAM* function by measurement of *PAM* amidation activity in  
125 serum from non-diabetic white individuals from the Oxford Biobank<sup>17</sup>. *PAM* activity  
126 was measured in 24 heterozygous carriers of the p.S539W allele, 27 heterozygous  
127 and 21 homozygous carriers of the p.D563G allele and age, sex and BMI matched  
128 non-carriers. We observed a 52% reduction in amidation activity in heterozygous  
129 carriers of the p.S539W allele compared to non-carriers (188±13 vs 392±13  
130 pmol/ml/hr  $p=9.3 \times 10^{-15}$ ), (**Fig. 1a**). Similarly, we observed a 20% (300±11 vs 370±14  
131 pmol/ml/hr,  $p=0.0008$ ) and 38% (272±10 vs 472±17 pmol/ml/hr,  $p=1.4 \times 10^{-9}$ )  
132 decrease in *PAM* serum activity in heterozygous and homozygous carriers of  
133 p.D536G compared to non-carriers, respectively (**Fig. 1b**).

134 Concomitantly, to understand how loss of *PAM* affects systemic processes  
135 influencing diabetes onset, we created an inducible *Pam* whole-body knockout  
136 mouse model (UBC-Er2-Cre *Pam*<sup>fl/fl</sup>, **Supplementary Fig. 1a**). *Pam*<sup>fl/fl</sup> mice were  
137 crossed with mice expressing a tamoxifen-inducible Cre-Ert2 fusion gene under the  
138 control of the human ubiquitin C (UBC) promoter<sup>18</sup>, and UBC-Er2-Cre *Pam*<sup>fl/fl</sup> and  
139 littermates of genotype *Pam*<sup>fl/fl</sup> were treated with tamoxifen at 4 weeks of age to  
140 generate *Pam* whole-body knockouts (hereby referred to as UBC-Cre *Pam*<sup>fl/fl</sup>) or  
141 control tamoxifen-treated *Pam* wild type littermates (or *Pam*<sup>fl/fl</sup>). Effective *Pam*<sup>fl/fl</sup>  
142 allele recombination and lack of *Pam* expression in UBC-Cre *Pam*<sup>fl/fl</sup> mice was  
143 assessed by gene expression and *Pam* ablation in different tissues (**Supplementary**  
144 **Fig. 1b-d**). Supporting the observations in individuals carrying loss of function alleles

145 (Fig. 1a, b), PAM amidation activity was absent in the whole-body knockout mice  
146 (Fig. 1c, Supplementary Fig. 1e).

147 **Postprandial GLP-1 concentration is increased in PAM LoF allele carriers and**  
148 **Pam knockout mice**

149 Having demonstrated the functional impact of p.D536G and p.S539W on PAM  
150 amidation activity *in vivo* we assessed the impact of this on postprandial amidated,  
151 unamidated and total (sum of amidated and unamidated) plasma GLP-1  
152 concentration in humans. We retrospectively examined amidated GLP-1 levels in two  
153 Danish Cohorts (AdditionPRO and Family studies – **Supplementary Table 1**)<sup>20,21</sup>. In  
154 the Family Study, amidated plasma GLP-1 levels (7-36 amide and 9-36 amide) were  
155 measured at 10 timepoints following an OGTT. We compared GLP-1 profiles and  
156 the AUC<sub>120</sub> in 26 Danish carriers of the p.D536G allele and 56 matched non-carriers  
157 (Fig. 2a)<sup>19, 20</sup>. The peak amidated GLP-1 concentration was higher in the carriers of  
158 the p.D536G allele (17.7±1.3 vs 23.9±3.4 pmol/L, p=0.04), as was the overall  
159 postprandial exposure, measured by GLP-1 AUC<sub>120</sub> (2498±168 vs 3251±303 pmol.L<sup>-1</sup>.min, p=0.02). Only 3 heterozygous carriers of the p.S539W allele were identified in  
160 the Family study participants. This study was underpowered to detect a difference in  
161 carriers of p.S539W and did not demonstrate a significant difference (1340±220 vs  
162 1895±62 pmol.L<sup>-1</sup>.min., p=0.13) (Fig. 2b).

164 The observation of increased GLP-1 concentration in carriers of PAM diabetes risk  
165 alleles is discordant with prior studies which demonstrated reduced GLP-1  
166 concentrations in individual with pre-diabetes and diabetes compared with non-  
167 diabetic individuals<sup>21-23</sup>. We sought to prospectively re-confirm the impact of PAM  
168 deficiency on postprandial GLP-1 levels and assess the consequence of altered  
169 GLP-1 levels on the incretin response using an isoglycaemic clamp, the gold

170 standard measure of the incretin response<sup>24</sup>. We performed a recruit-by-genotype  
171 study in 19 white normoglycaemic carriers of the presumed complete LoF allele  
172 p.S539W from the Oxford Biobank and on 19 age, sex and BMI matched non-  
173 carriers. We measured amidated and glycine extended GLP-1 concentration (both of  
174 which are biologically active) and calculated the total GLP-1 concentration at 10 time  
175 points following a 75g oral glucose load. The total (sum of amidated and  
176 unamidated) GLP-1 profiles were significantly higher in carriers compared to non-  
177 carriers ( $p=0.024$ ) (**Fig. 2b-c**). The mean  $AUC_{240}$  was higher in carriers compared to  
178 non-carriers (Total GLP-1:  $7692 \pm 304$  vs  $6887 \pm 230$  min.pmol/L  $p=0.04$ ).  
179 Importantly, there were no significant differences in insulin or glucose profiles  
180 between genotypes or ratio of amidated to non-amidated GLP-1 at any time point  
181 (**Table 1**).

182 Consistent with our observation in human carriers of PAM LoF alleles, in UBC-Cre  
183 *Pam*<sup>fl/fl</sup> knockout mice, total GLP-1 was not different in the fasted state but  
184 significantly higher compared to control after oral glucose load (**Supplementary Fig.**  
185 **3d**). Importantly, content of GLP-1 in duodenum and jejunum of UBC-Cre *Pam*<sup>fl/fl</sup>  
186 mice lacking Pam was identical to that of control *Pam*<sup>fl/fl</sup> littermates (**Supplementary**  
187 **Fig. 3a-b**), and DPP4 activity was similarly unchanged between the two groups  
188 (**Supplementary Fig. 3c**). A similar increase in GLP-1 was also obtained in refed  
189 UBC-Cre *Pam*<sup>fl/fl</sup> mice compared to *Pam*<sup>fl/fl</sup> (**Fig. 2d**). These data indicate that the  
190 increase in GLP-1 after glucose challenge or feeding in mice lacking *Pam* is not due  
191 to differences in GLP-1 production or DPP4 activity, but rather on altered GLP-1  
192 secretion.

193

194 **Carriers of *PAM* LoF alleles and whole-body *Pam* knockout mice demonstrate**  
195 **GLP-1 resistance**

196 Having demonstrated elevated GLP-1 concentration in carriers of PAM LoF alleles  
197 we assessed the functional impact on postprandial glucose homeostasis by  
198 measuring the incretin effect. The incretin effect refers to the disposal of glucose  
199 related to the secretion of the gut released peptides, GLP-1 and glucose dependent  
200 insulinotropic polypeptide (GIP) in response to nutrient ingestion<sup>25</sup>. We quantified the  
201 incretin effect with the gold standard isoglycemic clamp in the same 19 p.S539W  
202 carriers and non-carriers from the Oxford Biobank<sup>25</sup>. Despite higher postprandial  
203 GLP-1 concentrations there was no difference in the incretin response in carriers  
204 compared to non-carriers (47.5% ± 14.4 vs 50.7% ± 11.3, p=0.50) (**Fig. 3a**). To  
205 quantify GLP-1 action, we compared the ratio of incretin effect to the peak total  
206 (amidated and unamidated) GLP-1. We found a 18% reduction in GLP-1 sensitivity  
207 as measured by  $GLP_{peak}:incretin$  effect ratio in carriers of p.S539W compared to non-  
208 carriers (0.69±0.05 vs 0.83±0.04, p=0.04) (**Fig. 3b**). To exclude contribution of GIP  
209 (the major contributor to the incretin effect in health) to the observed phenotype, GIP  
210 AUC was also assessed after measurement at 10 time points, no difference was  
211 observed between p.S539W allele carriers and non-carriers (**Table 1**).

212 Levels of additional amidated hormones (Gastrin-amide, Gastrin-Gly and CCK-  
213 amide) with relevance to glucose homeostasis were also assessed. There was no  
214 difference at baseline or at maximal stimulation in gastrin-gly, gastrin amide and  
215 CCK-amide levels between carriers and non-carriers (**Supplementary Figure 4** and  
216 **Table 1**).

217 To further delineate the mechanism of PAM deficiency on GLP-1 resistance, whole  
218 body and pancreas-specific mouse knockout models were studied. Induced whole



219 body *Pam* knockout (UBC-Cre *Pam*<sup>fl/fl</sup> mice) resulted in greater postprandial  
220 glycaemia during an OGTT than in wildtype control mice (**Fig. 3c**). Importantly,  
221 pancreas-specific knockout mice (PDX1-Cre *Pam*<sup>fl/fl</sup>) did not have altered glycemia  
222 following an OGTT, suggesting that *Pam* affects glycaemic control mostly through  
223 extra-pancreatic tissues (**Supplementary Fig. 5a**). Gastric emptying rate (GE), the  
224 predominant GLP-1 mechanism mediating postprandial glycaemic control, was  
225 measured by a paracetamol absorption test in UBC-Cre *Pam*<sup>fl/fl</sup> mice<sup>26, 27</sup>. Consistent  
226 with GLP-1 resistance ubiquitous loss of *Pam* caused an increased GE rate in UBC-  
227 Cre *Pam*<sup>fl/fl</sup> mice compared to control animals (**Fig. 3d**). Despite treatment with the  
228 GLP-1 receptor agonist (Exendin 4), the GE rate of *Pam* knockout mice remained  
229 faster than wildtype controls, also consistent with increased GLP-1 resistance in the  
230 absence of *Pam* (**Fig. 3e**). The difference in GE between murine whole-body *Pam*  
231 knockout and control was almost entirely abolished by treatment with GLP-1 receptor  
232 antagonist Exendin-9 (**Fig. 3f**), demonstrating that GLP-1 action is the major  
233 mediator of this difference in GE rate between whole-body *Pam* knockdown and  
234 control mice. To mechanistically explain the causes of GLP-1 resistance and  
235 increased gastric emptying in UBC-Cre *Pam*<sup>fl/fl</sup> mice, we analyzed the expression of  
236 the GLP1 receptor (*GLP1R*) in the gastric pylorus, which influences GE rate, and in  
237 other tissues. UBC-Cre *Pam*<sup>fl/fl</sup> mice had a 62% reduction in pyloric GLP-1R  
238 expression compared to *Pam*<sup>fl/fl</sup> littermates ( $p < 0.0001$ ) (**Fig. 3g**). Reduction in *GLP1R*  
239 expression was not observed in the other tissues tested (islet, and kidney) (**Fig. 3h-**  
240 **i**), whilst expression of other gastric hormone receptors in the pylorus were  
241 unchanged, with the exception of the GRP receptor. Circulating levels of GRP were  
242 also increased in response to a glucose load (**Supplementary Figure 5b-c**).

243

244 **PAM LoF alleles carriers demonstrate resistance to treatment with GLP-1RA**

245 Evidence of GLP-1 resistance in the physiological setting prompted examination of  
246 the therapeutic response to GLP-1RA. A meta-analysis of 1,119 patients treated with  
247 GLP-1RAs in 3 investigator led cohorts (IMI-DIRECT, GODARTs and PRIBA) was  
248 performed, where HbA1c was measured at initiation of GLP-1RA treatment and at 6  
249 months. Individuals in these studies were treated with liraglutide, exenatide or  
250 exenatide LAR. In non-carriers of the *PAM* LoF alleles the mean absolute HbA1c  
251 change across the 3 studies after GLP-1 treatment was -1.24% (13.6 mmol/mol).  
252 The meta-analysis demonstrated a significant reduction in HbA1c with 6 months of  
253 therapy with GLP-1RA in both carriers and non-carriers of *PAM* LoF alleles (**Fig. 4**).  
254 The absolute magnitude of this reduction was significantly less in heterozygous  
255 carriers of the p.S539W *PAM* allele with a mean change in HbA1c of 0.69% (7.5  
256 mmol/mol). This amounted to an absolute loss of 0.55% (6.0 mmol/mol) HbA1c  
257 lowering per allele,  $p=0.025$ . A suggestive albeit non-significant difference in  
258 absolute HbA1c lowering was observed in heterozygous carriers of p.D563G after  
259 GLP-1RA initiation (-0.25% (2.7mmol/mol) per allele,  $p=0.050$ ). The meta-analysis  
260 demonstrated a clinically meaningful reduction in this response to GLP-1RA in both  
261 carriers of the p.S539W or the p.D563G (**Fig. 4**). This represents a relative loss of  
262 either 44% or 20% of the HbA1c lowering associated with GLP-1 RA use  
263 respectively. Of note, in the DIRECT study, carriers of p.S539W had an  
264 independently significant reduction in response to GLP-1RA (-0.67% (7.3mmol/mol)  
265 per allele,  $p=0.034$ ). In these studies, 11.5% of p.S539W carriers and 18.5% of  
266 p.D563G carriers in whom GLP-1RA treatment was initiated achieved the  
267 recommended HbA1c target of <7% compared to 25.3% of non-carriers.

268 To determine if a reduced response to GLP-1RA was driven by a GLP-1 specific  
269 effect we also determined the effect of *PAM* genotype on the response to three other  
270 commonly used anti-diabetic drugs, DPP-4i, metformin, and sulphonylureas, in the  
271 same studies. No significant differences were detected in response to any these  
272 medications between carriers and non-carriers of the *PAM* LoF alleles  
273 **(Supplementary Table 3-5 and Supplementary Fig. 6).**

274 We then sought to reproduce this finding by examining the effect of *PAM* genotype  
275 on response to albiglutide therapy in the GSK-Harmony trial. The GSK data was not  
276 included in the meta-analysis due to considerable methodological differences (the  
277 option to intensify GLP-1RA therapy in non-responders, measurement of effect over  
278 8 months rather than 6 months and the relatively small glycemc effect seen with  
279 albiglutide). Both carriers and non-carriers of *PAM* LoF alleles again demonstrated a  
280 reduction in HbA1c at 8 months. The magnitude of the reduction was 0.63%,  
281 approximately half that seen in the meta-analysis. There was no difference in  
282 response to GLP-1RA between carriers and non-carriers of the *PAM* p.S539W  
283 (0.28% (3.1 mmol/mol), SE:0.18, p=0.12) and p.D563G (-0.04% (0.4 mmol/mol),  
284 SE:0.07, p=0.53) alleles. Given the inconsistent effect observed in the GSK-  
285 Harmony trial and the meta-analysis, which comprised of 3 different GLP-1RA, we  
286 sought to assess agonist-specific effects. Retrospective analysis by agonist,  
287 although underpowered, and comprising different study designs demonstrated a  
288 reduced response to liraglutide in carriers of p.D563G but not p.S539W (p.D563G –  
289 0.25% (2.7 mmol/mol), p=0.05 & pS539W -0.16%, p=0.55). Response to exenatide  
290 was reduced in carriers of p.S539W but not p.D563G (p.D563G –0.14% (1.5  
291 mmol/mol), p=0.54 & pS539W -0.81% (8.9 mmol/mol), p=0.035). There was no  
292 difference in response to albiglutide in either of the *PAM* T2D-risk allele carriers

293 (p.D563G -0.03% (0.3 mmol/mol), p=0.73 & pS539W 0.30% (3.3 mmol/mol),  
294 p=0.15) (**Supplementary Fig. 7**). There was no significant effect of genotype on  
295 weight change for either p.S539W (-0.06kg, 95%CI [-1.26,1.14]) or p.D563G (0.27kg,  
296 95%CI [-0.29,0.82]) in the albiglutide treated Harmony study.

297 To further exclude an abnormal pancreatic response to GLP-1, we assessed the  
298 response to GLP-1RA treatment *in vitro* in a human beta-cell model EndoC-βH1 to  
299 determine the effect of PAM loss on insulin secretion. No difference between  
300 baseline insulin secretory response and glucose and GLP-1 stimulated insulin  
301 secretory response was demonstrated between control and PAM knockdown  
302 (**Supplementary Fig.8a**). Similarly, islets isolated from UBC-Cre Pam<sup>fl/fl</sup> mice and  
303 Pam<sup>fl/fl</sup> littermates and treated with GLP-1 (both amide and glycine-extended) had  
304 similar levels of insulin secretion (**Supplementary Fig. 8b**).

## 305 **DISCUSSION**

306 Translating genome wide association signals in T2D, into clinically useful information  
307 has been challenging. In this study we demonstrate how in-depth physiological  
308 characterization of a GWAS signal can lead to biological insight in T2D and  
309 subsequent focused examination of pharmacogenetic studies can provide  
310 implications for a currently available treatment. We demonstrated that two LoF  
311 alleles in PAM resulted in reduced PAM activity and caused GLP-1 resistance in the  
312 physiological and pharmacological setting.

313 Using tissue specific *Pam* knockout in mice allowed an assessment of where  
314 resistance is occurring. The observation of significantly higher blood glucose  
315 concentration in whole-body knockout but not in pancreas specific knockout upon  
316 oral glucose delivery suggests the dominant effects of *PAM* T2D-risk alleles on  
317 glycaemic regulation is occurring outside the pancreas. The demonstration of  
318 reduced GLP-1R expression in the pylorus, a regulator of GE rate, and  
319 demonstration of increased GE rate in mice regardless of GLP-1 abundance is highly  
320 suggestive that this is the mechanism driving GLP-1 resistance. Supportive of this  
321 mechanism was the reduction in difference in GE between whole body *Pam*  
322 knockout mice and controls when both were treated with exendin-9 (a GLP-1  
323 antagonist). It is important to note GE rate did not completely normalize and this may  
324 suggest the contribution of another amidated peptide. Together these data support  
325 the interpretation that GLP-1 levels were elevated in models of PAM deficiency due  
326 to GLP-1 resistance.

327 Given that delay to adequate treatment has been shown to increase diabetic  
328 complications, this raises concern about the use of GLP-1 receptor agonists in  
329 carriers *PAM* LoF alleles<sup>5</sup>. Importantly, we demonstrate that there was no impact of

330 *PAM* genotype on response to metformin, sulphonylurea, or DPP-4i with the latter  
331 two medications considered alternate second line medication choices in individuals  
332 without heart disease or renal impairment.

333 As pharmacogenetic cohorts increase in size and more alleles are identified which  
334 predict treatment response, a likely development will be the development of  
335 polygenic risk scores which predict likely response of an individual to the various  
336 diabetes agents.

### 337 **Conclusion**

338 In conclusion, mechanistic examination of the T2D *PAM* locus revealed that carriers  
339 of LoF alleles have reduced serum enzyme activity and GLP-1 resistance. The GLP-  
340 1 resistance in these carriers resulted in a specific and clinically meaningful  
341 reduction in response to exenatide and liraglutide. Data from a *Pam* mouse knockout  
342 model suggests that the mechanism of GLP-1 resistance is linked to dysregulated  
343 GE. The use GLP-1RA will not be as efficacious at reducing HbA1c in carriers of  
344 *PAM* T2D risk alleles.

### 345 **Acknowledgements**

346 ALG is a Wellcome Trust Senior Fellow in Basic Biomedical Science. MIM was a  
347 Wellcome Senior Investigator and NIHR Senior Investigator. ERP was a Wellcome  
348 Trust New Investigator (102820/Z/13/Z). BH is supported by a  
349 Diabetes UK RD Lawrence Fellowship 19/0005965. This work was funded by the  
350 Wellcome Trust (095101 [ALG], 200837 [ALG], 098381 [MIM], 106130 [ALG, MIM],  
351 203141 (ALG, MIM], 203141 [MIM]), Medical Research Council (MR/L020149/1)  
352 [MIM, ALG, FK, ATH], European Union Horizon 2020 Programme (T2D Systems)  
353 [ALG, TH], and NIH (U01-DK105535; U01-DK085545) [MIM, ALG] and UM-

354 1DK126185 [ALG], the National Institute for Health Research (NIHR) Oxford  
355 Biomedical Research Centre (BRC) [ALG, MIM, FK]. The views expressed are those  
356 of the author(s) and not necessarily those of the NHS, the NIHR or the Department  
357 of Health. The study was supported by the Novo Nordisk Foundation (Grant  
358 number NNF18CC0034900). The study was supported by a grant by Boehringer  
359 Ingelheim (MS). The work leading to this publication has received support from the  
360 Innovative Medicines Initiative Joint Undertaking under grant agreement n°115317  
361 (DIRECT), resources of which are composed of financial contribution from the  
362 European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA  
363 companies' in-kind contribution. This publication is based on research using data  
364 from GSK (HARMONY trials) that has been made available through secured access.  
365 GSK has not contributed to or approved, and is not in any way responsible for, the  
366 contents of this publication. We thank both GSK  
367 and [www.ClinicalStudyDataRequest.com](http://www.ClinicalStudyDataRequest.com) for providing us data and access. The  
368 ADDITION-PRO study was funded by an unrestricted grant from the European  
369 Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular  
370 Disease Risk Reduction in Patients with Diabetes (74550801), by the Danish Council  
371 for Strategic Research and by internal research and equipment funds from Steno  
372 Diabetes Center. This work was supported by the European Union's Horizon 2020  
373 research and Innovation programme (Grant Agreement No 667191). AJ is supported  
374 by the Danish Council for Independent Research, European Union, FP7, Marie Curie  
375 Actions, IEF, Lundbeck Foundation (R140-2013-13313), Novo Nordisk Foundation  
376 and Danish Diabetes Academy (NNF17SA0031406, PDMI002-18)  
377 The PRIBA study was funded by A National Institute for Health and Care Research  
378 (U.K.) Doctoral Research Fellowship (DRF-2010-03-72, Jones) and supported by the

379 National Institute for Health Research and Care Clinical Research Network. The  
380 views expressed are those of the author(s) and not necessarily those of the NIHR or  
381 the Department of Health and Social Care.

382 **Conflicts**

383 ERP has received honoraria from Lilly, Sanofi and Illumina. MIM holds stock options  
384 in Roche. ALG's spouse is an employee of Genentech and holds stock options in  
385 Roche.



386 **Online Methods:**

387 ***Methods***

388 **Human Subjects**

389 All volunteers provided written informed consent. The protocol was approved by  
390 Oxford B NRES Research Ethics Committee. The study was registered prospectively  
391 (ClinicalTrials.gov:NCT02723110).

392 **Human Biochemical and Clinical methods**

393 To establish the impact of T2D associated LoF alleles (p. D536G & p.S539W) on  
394 PAM enzyme activity in carriers, stored serum samples from the Oxford Biobank  
395 (OBB) and a prospective collected serum from a recruit-by-genotype study were  
396 analyzed<sup>17</sup>. PAM activity was measured using a previously described radiotracer  
397 method (supplementary section 1.1) in 24 heterozygous carriers of p.S539W, 27  
398 heterozygous carriers of p.D563G and 21 homozygous carriers of p.D563G and age,  
399 sex and BMI matched non-carriers<sup>28, 29</sup>. All individuals were normoglycaemic and of  
400 white European background and measurements were performed in triplicate.

401 Plasma glucose was measured using the ilab 650 Analyser (Instrumentation  
402 Laboratory Ltd, Warrington, UK) as previously described<sup>17</sup>. Serum insulin  
403 concentrations were measured using the Human Specific Insulin RIA Kit (EMD  
404 Milipore, Billerica, USA)<sup>17</sup>. Radioimmunological determinations of intact, amidated  
405 and glycine extended plasma GLP-1 concentration were performed as described  
406 previously<sup>30</sup>. Gastrin and CCK were measured using non-commercial antibody-  
407 based assays as previously described<sup>11, 31</sup>.

408 Retrospective analysis of intact GLP-1 (7-36 amide and 9-36 amide) profiles  
409 following a 75g OGTT was performed in two Danish cohort studies (AdditionPro and

410 Family Study)<sup>19, 20</sup>. Normoglycaemic carriers of the T2D -risk alleles p.S539W and  
411 p.D563G were matched for age, BMI and sex to two non-carriers. Demographics of  
412 the 2 studies are provided in table S1 (**Supplemental section 2.1**). Individuals with  
413 T2D were excluded prior to analysis to minimize effects associated with treatment  
414 and avoid reduction in incretin effect observed in overt hyperglycaemia<sup>32</sup>.

415 Twenty carriers of the low frequency *PAM* p.S539W T2D-risk LoF allele and twenty  
416 matched non-carriers were prospectively recruited to into a double blind,  
417 observational, recruit-by-genotype study to corroborate findings of the retrospective  
418 analysis and to assess the impact of *PAM* genotype on plasma GLP-1 levels and the  
419 incretin response. Genotype was reconfirmed on day 1 of the study (**table 1**). One  
420 pair was excluded due to genotyping error. Subjects were recruited from the OBB  
421 and all were of white European background and normoglycaemic. Subjects  
422 underwent a 4 hour frequently sampled OGTT and matched isoglycaemic clamp (the  
423 gold standard assessment of the incretin effect) (**Supplemental information,**  
424 **section 4.1**) on separate study days<sup>25</sup>. Blood samples were collected at 10 time  
425 points for biochemical analysis and blood glucose was measured in real-time every 5  
426 min to facilitate the isoglycaemic clamp. The effect of genotype on the various  
427 outcomes was assessed using a 2-sided t-test, RM-ANOVA or mixed effect analysis  
428 as appropriate. All data are displayed as mean  $\pm$  SD.

429 The study utilized an adaptive study design with an interim analysis at 40 volunteers  
430 (20 v 20) with the possibility of adding an additional 20 volunteers to the study (10 v  
431 10) if the criteria for futility or clear effect are not met. The criteria were; stop and  
432 reject null hypothesis if  $t > 2.490$  and stop and accept null hypothesis if  $t < 1.033$ . If  
433 the  $t$  fell between these values an additional 20 volunteers (10 v10) were to be  
434 recruited. The decision to stop or include additional volunteers was be based on the

435 incretin effect (primary outcome) and prospectively listed on the clinicaltrials.gov  
436 registry.

437 This provided a 90% chance of detecting a difference of 10% with an alpha 5%  
438 (estimated SD of 10%) in incretin effect at the first stopping point.

#### 439 *Pharmacogenetics*

440 Response to GLP-1RA and other oral hypoglycemic agents (DPP-4i, metformin and  
441 sulphonylurea) were compared between carriers and non-carriers of *PAM* p.S539W  
442 and p.D563G carriers. Response to GLP-1RA was initially assessed by comparing  
443 the response to treatment of 1,119 patients with T2D treated with GLP-1RA in a  
444 meta-analysis of the three similar cohorts (GODARTS, IMI-DIRECT and PRIBA) and  
445 replication was sought in the methodologically different GSK-Harmony Trial  
446 (N=1,292, predominantly albiglutide). Cohort demographics and study design are  
447 provided in supplemental information (section 3.1). In the discovery meta-analysis,  
448 response was determined in all 3 studies by HbA1c change from baseline (day of  
449 initiation of medication) to the HbA1c at 6 months of therapy. The clinical model for  
450 assessing treatment response was developed using linear regression and backward  
451 elimination through the stepAIC function in the MASS package in R<sup>33</sup>. A linear  
452 regression was performed adjusting for clinical covariates: baseline HbA1c, age at  
453 diagnosis, duration of diabetes, number of oral glycaemic agents (OHA) at initiation of  
454 GLP-1RA, insulin dose and change in OHA. A meta-analysis was performed using a  
455 fixed effects model in the Forrest package of R<sup>34</sup>. In the GSK-Harmony trial data the  
456 effect of genotype on HbA1c was determined using a similar model. The method  
457 differed due to differences in study design which include that the HbA1c was  
458 measured at baseline and at 8 months to determine the change in HbA1c.  
459 Significantly, in the GSK-Harmony studies there was the opportunity for dose

460 increase at 5 weeks if it was felt that participants were not responding. The study  
461 was conducted over multiple sites so in addition to the model used in the discovery  
462 meta-analysis study “site” was included as a factor in the clinical model. Finally, to  
463 examine agonist specific effects, data from all 4 studies were pooled in “a by-agonist  
464 meta-analysis” (**Figure 5**). The effect of *PAM* genotype on metformin and  
465 sulphonylurea response was also assessed in GoDARTs and IMI-DIRECT and used  
466 the same model as the assessment of GLP-1 in these cohorts. Details of cohorts  
467 for these analyses are provided in supplemental information (**Section 3.1**).

#### 468 *Insulin secretion in the human EndoC-βH1 cell line*

469 EndoC-βH1 cells were cultured, plated in a 96-well plate and transfected with siRNA  
470 as described previously<sup>7, 35</sup> or incubated for 48 h with either DMSO or 500μM 4-  
471 Phenyl-3-butenoic acid (PBA, Sigma #155322). Plated cells were incubated the  
472 night prior to the experiment in culture medium with 2.8 mM glucose. On the day of  
473 the assay, cells were incubated in glucose-free culture medium for 1hr and then  
474 stimulated with either 1 mM or 10 mM glucose. The latter stimulation was  
475 complemented with either GLP-1 (7-36) amide (1 nM, BACHEM #4030663),  
476 tolbutamide (200 μM, Fluka Analytical #T0891), or Forskolin (10 μM, Merck #F3917).  
477 Residual cells were removed by centrifuging the collected supernatants (4°C, 700g,  
478 5min) and 50μL of the supernatant was stored at -20°C until the assay. Samples to  
479 measure insulin content were harvested in 100μL of acid ethanol (1.5% conc. HCl,  
480 75% ethanol, and 23.5% distilled H<sub>2</sub>O) in the 96-well plate and stored at -20°C.  
481 Insulin concentrations of both supernatants and cellular contents were determined  
482 using Insulin (human) AlphaLISA Detection Kit (PerkinElmer). Data presented are  
483 the result of 3 biologically independent experiments on two different passages of  
484 EndoC-βH1 lines. Each biological replicate is the average of 3 technical replicates.

485 We used a 2-way ANOVA followed by a Tukey post hoc test to evaluate the  
486 interaction between the transfection (siControl vs. siPAM) or treatment (DMSO vs.  
487 PBA), and the various stimulations of insulin secretion detailed above. (add  
488 sequences of siControl vs. siPAM)

#### 489 **Generation & Characterisation of Pam knockout mouse models**

490 All animals were housed in a pathogen-free animal facility at the Institute of  
491 Molecular Health Sciences at ETH Zürich. Mice were maintained in a temperature-  
492 and humidity-controlled room on a 12 h light/ dark cycle (lights on from 6:00 to  
493 18:00). Mice were given ad libitum access to a standard laboratory chow and water.  
494 All animals were at least 8 weeks of age. Experiments were performed  
495 independently in both sexes, and figures display representative experiments. Pam<sup>fl/fl</sup>  
496 mice were generated in the ETHZ EPIC facility by injecting blastocysts with Pam-  
497 targeted ES cells obtained from EUMMCR (clone EPD0607\_1\_A11). Founders  
498 (tm1a – Pam<sup>flneo/flneo</sup>) were screened for the presence of the targeted allele and  
499 neo cassette, and bred with FLP-Deleter (B6.129S4-Gt(ROSA)26Sortm1(FLP1)  
500 Dym/RainJ) to remove the neo cassette (to obtain tm1c – Pam<sup>fl/fl</sup> allele)  
501 (**Supplementary Fig. 1A**). UBC-Cre mice (Tg[UBC-cre/ERT2]1Ejb - purchased from  
502 Jackson Laboratories) were crossed with Pam<sup>fl/fl</sup> to obtain UBC-Cre Pam<sup>fl/fl</sup>. To  
503 create PDX1-Cre Pam<sup>fl/fl</sup> mice, B6.FVB-Tg(Pdx1-cre)6Tuv/J were crossed with  
504 Pam<sup>fl/fl</sup> and backcrossed. All animal experiments were in accordance with  
505 institutional guidelines and approved by the kantonale Veterinärämte Zürich.

506 *Tamoxifen injection for Cre-mediated Pam<sup>fl/fl</sup> allele recombination*

507 Mice at 4 weeks of age were administered daily intraperitoneal injections of 2 mg  
508 tamoxifen (T5648, Sigma) for 5 days, dissolved at a concentration of 20 mg/mL in  
509 10% Ethanol/90% corn oil.

#### 510 *Oral Glucose Tolerance Test*

511 Mice were fasted for 6 h and D-glucose (Sigma, 49139) solution (2 g/kg)  
512 administered by gavage. Blood glucose values were measured by tail nick with a  
513 Bayer Contour XT glucometer at 0, 15, 30, 45, 60, and 120 min after injection.

#### 514 *GLP-1 measurement*

515 Mice were injected intraperitoneally with dipeptidyl peptidase-4 (DPP-4) inhibitor  
516 Sitagliptin (Merck, 3 mg/kg) at  $t = 0$  and after 30 min, D-glucose (Sigma Aldrich  
517 2 g/kg) was administered orally by gavage. Blood was sampled 5 min thereafter  
518 and added to 5  $\mu$ l Aprotinin (Sigma, 5 mg/ml), 2  $\mu$ l EDTA (0.5 M) and, 3  $\mu$ l  
519 DPP-4 Inhibitor (Millipore) on ice. Blood was collected from the tail vein, serum  
520 isolated and GLP-1 content was measured with GLP-1 ELISA (Merck).

#### 521 *Paracetamol gastric emptying assays*

522 10 mg/mL of paracetamol (Acetaminophen, Panadol) and 0.2 g/mL glucose in PBS  
523 were administered by gavage (at a final dose of 0.1 mg/g and 2 mg/g of body  
524 weight). Blood was collected from tail vein before gavage, at 15, 30, 45 and 60  
525 minutes after gavage, and concomitantly blood glucose was measured with a Bayer  
526 Contour XT glucometer. Serum was used to measure paracetamol at each time point  
527 (Paracetamol Test Kit Triple Enzyme, K8003, CLS diagnostics, UK).

528 In experiments using Exendin 9 (Exendin 9-39, Biozol MBS826292-5), the  
529 compound was injected intraperitoneally 5 min prior to gavage at dose of 50  
530  $\mu$ g/mouse.

531 In assays including Exendin 4 (Exenatide, Bydureon, AstraZeneca), the compound  
532 was injected intraperitoneally 30 min prior gavage at the concentrations of 10  
533 nmol/kg.

534

535 *GLP-1-stimulated insulin secretion in mouse pancreatic islets*

536 Mouse pancreatic islets were isolated from adult *Pam<sup>fl/fl</sup>* and UBC-Cre *Pam<sup>fl/fl</sup>*  
537 littermates. After sacrifice, a total of 2 ml of Liberase (5 mg/ml) (Sigma  
538 05401127001, diluted in HBSS buffer, GIBCO, 14170-112) was injected through the  
539 common bile duct to perfuse the whole pancreas. The perfused pancreas was  
540 dissected and incubated at 37°C for 17 min. Digested exocrine cells and intact islets  
541 were separated via centrifugation (2400 rpm for 20 min with very slow acceleration  
542 and no braking) over Histopaque-1077 (Sigma, 10771), and intact islets were  
543 manually picked under the microscope. Islets from each mouse were kept separated  
544 and were cultured in RPMI 1640 with 10% FBS and 100 U/ml penicillin/streptomycin  
545 overnight, while genotype was reconfirmed by PCR.

546 The next day, islets were picked and equilibrated in Dulbecco islet secretion media +  
547 0.2% BSA with 1 mM glucose for 30 min in p24-well plates, then transferred to  
548 experimental conditions for 1 h. Each experimental condition (250 µL of Dulbecco  
549 islet secretion media with 1 mM glucose, or with 10 mM glucose, or with 10 mM  
550 glucose + 1 nM GLP-1 (7-36amide, product n. 4030663, Bachem Switzerland) or  
551 with 10 mM glucose + 1 nM GLP-1 (7-37 glycine extended, product n. 4034865,  
552 Bachem Switzerland) had exactly 5 equally sized islets and was tested in three  
553 technical replicate per mouse. At the end of the secretion assay, islets were  
554 collected and disrupted in acid/ethanol solution (95% v/v absolute ethanol, 5% v/v  
555 acetic acid and 0.1% v/v Triton X-100), sonicated briefly, spun down and supernatant  
556 diluted 1:500 to measure insulin content with an insulin ELISA (Elpco), while  
557 supernatant was spun down to remove shed cells, and insulin concentration  
558 measured. Insulin secretion is expressed as the ratio between total secreted insulin



559 and total islet insulin. Islets not used for secretion assays were briefly washed and  
560 placed in Trizol for RNA quantification.

#### 561 *RNA isolation and quantification*

562 TRIzol reagent (Invitrogen, 15596-026) was used for RNA isolation according to the  
563 manufacturer's protocol. RNA was reverse transcribed using High Capacity cDNA  
564 Reverse Transcription Kit (Applied Biosystems, 4368813). Quantitative PCR was  
565 performed in an LC480 II Lightcycler (Roche) and using gene specific primers and  
566 Sybr Fast 2x Universal Master mix (Kapa biosystems, KK4611). Results were  
567 normalized to 36b4 mRNA levels.

#### 568 *HPLC-based YVG amidation assay*

569 Custom made Dansyl-YVG peptide, and control amidated product Dansyl-YV-amide,  
570 was synthesized by JPT peptide technologies GmbH. The amidation assay method  
571 is a slight adaptation of the method described by Eipper and colleagues (Czyzyk et  
572 al., 2005; Kolhekar et al., 1997; Ul-Hasan et al., 2013). Tissues were flash frozen,  
573 then amidation buffer added (NaTES pH7 20 mM, Mannitol 10 mM, Triton X-100 1%  
574 v/v freshly open at each lysis buffer preparation) additioned with fresh 1 mM  
575 pepstatin, 1 mM PMSF, 1 mM soya beans trypsin inhibitor (all from Sigma). Samples  
576 were homogenized for 2 min at 30Hz with TissueLyser II (Qiagen), then underwent  
577 three freeze-thaw cycles before removing debris with centrifugation at 2000 rpm for  
578 15 min at 4°C, and supernatant quantified and stored frozen. 50 mg of tissue lysate  
579 was added to obtain a total of 50 µL of the amidation assay buffer composed of:  
580 Catalase 100 ug/mL (freshly prepared), 2 mM L-ascorbic acid (freshly prepared),  
581 ZnCl<sub>2</sub> 2 µM, CaCl<sub>2</sub> 2 µM, CuSO<sub>4</sub> 75 µM, NAMES 100 mM, pH 5.5, 0.15 mM Dansyl-  
582 YVG. All chemicals were from Sigma. The reaction was then incubated for 2, 4 or 6 h  
583 in a 37°C water bath before being collected and spun down in Amicon® Ultra 0.5 mL

584 filter vial (Merck Millipore). The flow through was then measured via  
585 chromatographic analysis of chemically converted Dansyl-YVG into Dansyl-YV-NH<sub>2</sub>  
586 or Dansyl-YVG(OH) YVG substrate into the Dansyl-YV- hydroxyglycine intermediate  
587 and the amidation product dansyl-YV-N<sub>2</sub> by means of high-performance liquid  
588 chromatography (HPLC) as described by Ul-Hasan and colleagues (REF PMID:  
589 23994590). The absorbance of substrate, intermediate and product were detected at  
590 220 and 280 nm on a C18 analytical column over a linear gradient ranging from 22%  
591 to 25% of solvent (acetonitrile) in 20 min.


592

### 593 **Data Availability**

594 All other data generated or analysed during this study are included in this published  
595 article (and its supplementary information files). IMI-DIRECT data access is available  
596 on request ([DIRECTdataaccess@dundee.ac.uk](mailto:DIRECTdataaccess@dundee.ac.uk)). HARMONY data can be  
597 requested via [clinicalstudydatarequest.com](https://clinicalstudydatarequest.com). De-identified participant-level data  
598 generated in this study from the Oxford Biobank can be requested from the  
599 corresponding author pending approval from the Oxford Biobank.

600

601



602

603

604

605 **Figure 1. Amidation activity in *PAM* missense allele carriers and in *Pam* knockout**  
606 **mice.**

607


608 **A:** Panel A demonstrates the reduction in serum enzyme activity in heterozygous carriers of  
609 p.S539W (N=19) compared to age, sex and BMI matched non-carriers (N=19) (left). All  
610 samples were measured in triplicate and the data points presented above are the mean of  
611 the triplicates. Dashed lines connect the BMI, age and gender matched non-carrier to the  
612 corresponding carrier.

613 **B:** Panel B demonstrates the reduction observed in heterozygous (N=27) and homozygous  
614 carriers (N=21) of p.D563G compared to age, sex and BMI matched non-carriers  
615 respectively. Data have been normalised to non-carriers to allow comparison between  
616 genotypes. Carriers were 1:1 matched for age, gender, and sex. All samples were measured  
617 in triplicate and the data points presented above are the mean of the triplicates. The long  
618 black line represents the mean amidating activity +/- the SEM.

619 **C:** Panel C demonstrates the percentage of PAM-mediated conversion of Dansyl-YVG-  
620 COOH intermediate and Dansyl-YV-NH<sub>2</sub> product from Dansyl-YVG in an amidation assay in  
621 pituitary extracts UBC-Cre *Pam<sup>fl/fl</sup>* mice or *Pam<sup>fl/fl</sup>* (N=2,2) after 2 hours from the start of the  
622 assay. The error bar represents SD.

623

**Figure 2**




624

625 **Figure 2. GLP-1 profiles of carriers of PAM loss-of-function alleles**

626 **A-B:** Panel A & B demonstrate the amidated GLP-1 profile of carriers of p.D536G (A) and  
 627 p.S539W (B) and age gender and BMI matched non-carriers following a 75g OGTT in the  
 628 Family Study. Each data point is the mean amidated GLP-1 concentration  $\pm$  SD. Panel A  
 629 demonstrated the amidated GLP-1 profiles of 24 carriers of p.D536G and 48 matched non-  
 630 carriers. Panel B demonstrates the amidated GLP-1 profiles of 3 carriers of p.S539W and 6  
 631 non-carriers.

632 **C:** Panel C demonstrates the total GLP-1 (sum of amidated and non-amidated GLP-1)  
 633 plasma profiles of 19 heterozygous carriers of S539W and 19 age, gender and BMI matched  
 634 non-carriers in the prospectively performed 75g OGTT. Each data point is the total GLP-1  
 635 concentration  $\pm$  SD. Analysis was performed using RM-ANOVA. Note: total GLP-1 is  
 636 displayed as amidated and non-amidated GLP-1 was measured but there was no difference  
 637 in the ratio between amidated and non-amidated GLP-1 at any time point and both forms of  
 638 GLP-1 have equal biological activity<sup>36</sup>.

639 **D:** Amidated GLP-1 concentration pre- and 30 min after re-feeding in UBC-Cre *Pam<sup>fl/fl</sup>* mice  
 640 or *Pam<sup>fl/fl</sup>* littermates (N=5,5). Error bar represents SD. Analysis was via non-paired T-test.  
 641



642  
643  
644

645  
646

647 **Figure 3. PAM loss leads to GLP-1 Resistance**

648 **A:** Panel A demonstrates the incretin effect in 19 heterozygous carriers of p.S539W and 19  
649 matched non-carriers as measured by the IV glucose required as a percentage of 75g to re-  
650 produce a glucose curve associated with a 75g oral glucose load. Error bars represent SD.

651 **B:** Panel B demonstrates the ratio between peak GLP-1 concentration and incretin effect in  
652 19 heterozygous carriers of p.S539W and 19 matched non-carriers. This is a surrogate of  
653 GLP-1 sensitivity and demonstrate a significant reduction in GLP-1 sensitivity in carriers of  
654 S539W compared to non-carriers. Error bars represent SD.

655 **C:** Panel C demonstrates the blood glucose concentration after glucose load in UBC-Cre  
656 *Pam<sup>fl/fl</sup>* mice or *Pam<sup>fl/fl</sup>* littermates (N=7,7). Induced whole body Pam knockout (UBC-Cre  
657 *Pam<sup>fl/fl</sup>* mice) resulted in greater postprandial glycaemia during an OGTT than in wildtype  
658 control mice. Error bar indicates SD.

659 **D:** Plasma paracetamol concentration after oral paracetamol load which is a surrogate for  
660 gastric emptying rate. The higher concentrations of paracetamol concentration observed in  
661 Pam knockdown are consistent with more rapid paracetamol absorption and faster gastric  
662 emptying. This figure demonstrates significantly higher paracetamol concentration in the  
663 induced whole body Pam knockout (UBC-Cre *Pam<sup>fl/fl</sup>* mice) (N=7,7). Error bar indicates SD.

664 **E-F:** Panel E demonstrates the effect of whole body Pam knockout on gastric emptying  
665 during treatment with GLP-1 receptor agonist (exendin-4) as measured by the paracetamol  
666 absorption test (N=4,8). Paracetamol concentration is significantly higher in whole body Pam  
667 knockout compared to control. Figure F demonstrates the gastric emptying rate in during  
668 treatment with GLP-1 receptor antagonist (exendin-9) (N=4,8). Error bar indicates SD.


669 **G-I:** Figures G-I demonstrate reduced expression of the GLP-1 receptor in the pylorus of the  
670 stomach in whole body Pam knockdown (G) (N=5,5), and no change in expression in  
671 pancreatic islets (H) (N=2,2) or kidney (I) (N=3,3). Error bar indicates SD.

672

673

674

675



676

677 **Figure 4. Meta-analysis of the effect of carrying LoF alleles at p.D536G and**  
 678 **p.S539W on response to GLP-1RA therapy**

679 The effect of carrying p.D536G and p.S539W on treatment response to GLP-1RA. Each  
 680 study is displayed separately, and the effect size is indicated by the location of a solid box  
 681 with the 95% CI displayed either side. The line of no effect is indicated by a vertical dotted  
 682 line. The summary estimate of the effect of each allele is displayed below the individual  
 683 cohort summaries and is indicated by a solid black diamond with the center of the diamond  
 684 indicating the summary estimate and the lateral points the 95% CI. The effect is displayed is  
 685 the mean absolute HbA1c change between baseline and 6 months (% DCCT units). The  
 686 meta-analysis comprises 1,119 individuals across the 3 studies 130 carrier p.D563G and 26  
 687 carriers of pS539W.  
 688

689 **Table 1: Clinical & biochemical characteristics of genotype-based recall study**  
 690

	Non-carrier	p.S539W carrier	P Value
Age (years)	50.9 ± 5.8	50.6 ± 5.9	0.23
Sex (m/f)	13/6	13/6	1.0
BMI (kg/m <sup>2</sup> )	24.9 ± 3.3	24.4 ± 3.1	0.18
Waist : hip ratio	0.86 ± 0.1	0.87 ± 0.09	0.83
Glucose AUC (mmol.l-1.min-1)	1560 ± 226	1652 ± 301	0.23
Insulin AUC	8422 ± 3582	11530 ± 7769	0.09
Total GLP-1 auc (min.pmol/l)	6887 ± 230	7692 ± 304	0.04
Incretin effect (%)	50.7 ± 11.2	47.5 ± 14.4	0.50
Gastrin amide fold change	1.63 ± 0.43	1.47 ± 0.48	0.09
Gastrin gly fold change	1.06 ± 0.18	1.04 ± 0.49	0.71
CCK amide	3.12 ± 4.72	3.58 ± 4.34	0.78
TSH	1.54 ± 0.49	1.34 ± 0.53	0.26
GIP auc (min.pmol/l)	11781 ± 4725	11670 ± 5518	0.95

691  
 692 Data are presented as the mean ± SD. Fold change for gastrin was calculated as the ratio  
 693 between t<sub>0</sub> and t<sub>30</sub>. Fold change for CCK amide was calculated at t<sub>0</sub> and t<sub>60</sub>.  
 694



695 **References:**

- 696 1 IDF. International Diabetes Federation. IDF Diabetes, 7 ed. Brussels,  
697 Belgium: International Diabetes Federation, 2015. <http://www.diabetesatlas.org>.  
698 2015.
- 699 2 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, *et*  
700 *al.* Management of hyperglycemia in type 2 diabetes: a patient-centered approach:  
701 position statement of the American Diabetes Association (ADA) and the European  
702 Association for the Study of Diabetes (EASD). *Diabetes Care*. 2012; **35**: 1364-79.
- 703 3 Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The  
704 prevalence of meeting A1C, blood pressure, and LDL goals among people with  
705 diabetes, 1988-2010. *Diabetes Care*. 2013; **36**: 2271-9.
- 706 4 Dawed AY, Zhou K, Pearson ER. Pharmacogenetics in type 2 diabetes:  
707 influence on response to oral hypoglycemic agents. *Pharmacogenomics and*  
708 *personalized medicine*. 2016; **9**: 17-29.
- 709 5 Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, *et al.*  
710 Twelve type 2 diabetes susceptibility loci identified through large-scale association  
711 analysis. *Nat Genet*. 2010; **42**: 579-89.
- 712 6 Huyghe JR, Jackson AU, Fogarty MP, Buchkovich ML, Stancakova A,  
713 Stringham HM, *et al.* Exome array analysis identifies new loci and low-frequency  
714 variants influencing insulin processing and secretion. *Nature genetics*. 2013; **45**:  
715 197-201.
- 716 7 Thomsen SK, Raimondo A, Hastoy B, Sengupta S, Dai XQ, Bautista A, *et al.*  
717 Type 2 diabetes risk alleles in PAM impact insulin release from human pancreatic  
718 beta-cells. *Nat Genet*. 2018; **50**: 1122-31.
- 719 8 Prigge ST, Mains RE, Eipper BA, Amzel LM. New insights into copper  
720 monooxygenases and peptide amidation: structure, mechanism and function. *Cell*  
721 *Mol Life Sci*. 2000; **57**: 1236-59.
- 722 9 Eipper BA, Stoffers DA, Mains RE. The biosynthesis of neuropeptides:  
723 peptide alpha-amidation. *Annual review of neuroscience*. 1992; **15**: 57-85.
- 724 10 Czyzyk TA, Ning Y, Hsu M-S, Peng B, Mains RE, Eipper BA, *et al.* Deletion of  
725 peptide amidation enzymatic activity leads to edema and embryonic lethality in the  
726 mouse. *Developmental Biology*. 2005; **287**: 301-13.
- 727 11 Rehfeld JF, Stadil F. The effect of gastrin on basal- and glucose-stimulated  
728 insulin secretion in man. *J Clin Invest*. 1973; **52**: 1415-26.
- 729 12 Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N.  
730 Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in  
731 Eating and Glycemia in Health, Obesity, and After RYGB. *Physiological reviews*.  
732 2017; **97**: 411-63.
- 733 13 Mains RE, Alam MR, Johnson RC, Darlington DN, Back N, Hand TA, *et al.*  
734 Kalirin, a multifunctional PAM COOH-terminal domain interactor protein, affects  
735 cytoskeletal organization and ACTH secretion from AtT-20 cells. *J Biol Chem*. 1999;  
736 **274**: 2929-37.
- 737 14 Roberge JN, Gronau KA, Brubaker PL. Gastrin-releasing peptide is a novel  
738 mediator of proximal nutrient-induced proglucagon-derived peptide secretion from  
739 the distal gut. *Endocrinology*. 1996; **137**: 2383-8.
- 740 15 Persson K, Gingerich RL, Nayak S, Wada K, Wada E, Ahrén B. Reduced  
741 GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP  
742 receptor-deleted mice. *American journal of physiology Endocrinology and*  
743 *metabolism*. 2000; **279**: E956-62.

- 744 16 Sayegh AI. The role of bombesin and bombesin-related peptides in the short-  
745 term control of food intake. *Prog Mol Biol Transl Sci.* 2013; **114**: 343-70.
- 746 17 Karpe F, Vasan SK, Humphreys SM, Miller J, Cheeseman J, Dennis AL, *et al.*  
747 Cohort Profile: The Oxford Biobank. *Int J Epidemiol.* 2018; **47**: 21-21g.
- 748 18 Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, Cotsarelis G, *et*  
749 *al.* Deletion of the developmentally essential gene ATR in adult mice leads to age-  
750 related phenotypes and stem cell loss. *Cell Stem Cell.* 2007; **1**: 113-26.
- 751 19 Gjesing AP, Ekstrom CT, Eiberg H, Urhammer SA, Holst JJ, Pedersen O, *et*  
752 *al.* Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic  
753 polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.  
754 *Diabetologia.* 2012; **55**: 1338-45.
- 755 20 Johansen NB, Hansen AL, Jensen TM, Philipsen A, Rasmussen SS,  
756 Jorgensen ME, *et al.* Protocol for ADDITION-PRO: a longitudinal cohort study of the  
757 cardiovascular experience of individuals at high risk for diabetes recruited from  
758 Danish primary care. *BMC Public Health.* 2012; **12**: 1078.
- 759 21 Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, *et al.*  
760 GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type  
761 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.  
762 *Diabetes.* 2015; **64**: 2513-25.
- 763 22 Legakis IN, Tzioras C, Phenekos C. Decreased Glucagon-Like Peptide 1  
764 Fasting Levels in Type 2 Diabetes. *Diabetes Care.* 2003; **26**: 252-52.
- 765 23 Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial  
766 concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic  
767 patients. *Diabetes.* 2001; **50**: 609-13.
- 768 24 Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in  
769 type 2 (non-insulin-dependent) diabetes. *Diabetologia.* 1986; **29**: 46-52.
- 770 25 Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous  
771 glucose: studies in normal and diabetic subjects. *J Clin Invest.* 1967; **46**: 1954-62.
- 772 26 Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the  
773 deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its  
774 insulinotropic effect in healthy subjects. *Diabetes.* 2005; **54**: 2212-8.
- 775 27 Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG,  
776 *et al.* Comparative effects of prolonged and intermittent stimulation of the glucagon-  
777 like peptide 1 receptor on gastric emptying and glycemia. *Diabetes.* 2014; **63**: 785-  
778 90.
- 779 28 Mizuno K, Sakata J, Kojima M, Kangawa K, Matsuo H. Peptide C-terminal  
780 alpha-amidating enzyme purified to homogeneity from *Xenopus laevis* skin. *Biochem*  
781 *Biophys Res Commun.* 1986; **137**: 984-91.
- 782 29 Kolhekar AS, Mains RE, Eipper BA. Peptidylglycine alpha-amidating  
783 monooxygenase: an ascorbate-requiring enzyme. *Methods in enzymology.* 1997;  
784 **279**: 35-43.
- 785 30 Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma  
786 concentrations of amidated and glycine-extended glucagon-like peptide I in humans.  
787 *Diabetes.* 1994; **43**: 535-9.
- 788 31 Rehfeld JF. Accurate measurement of cholecystokinin in plasma. *Clinical*  
789 *chemistry.* 1998; **44**: 991-1001.
- 790 32 Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE,  
791 Michelsen BK, *et al.* Determinants of the impaired secretion of glucagon-like peptide-  
792 1 in type 2 diabetic patients. *J Clin Endocrinol Metab.* 2001; **86**: 3717-23.

793 33 Ripley WNVaBD. Modern Applied Statistics with S. Fourth edn: Springer}  
794 2002.  
795 34 Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package.  
796 2010. 2010; **36**: 48.  
797 35 Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M,  
798 Czernichow P, *et al.* A genetically engineered human pancreatic beta cell line  
799 exhibiting glucose-inducible insulin secretion. *J Clin Invest.* 2011; **121**: 3589-97.  
800 36 Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of  
801 glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy  
802 subjects are indistinguishable. *Diabetes.* 1993; **42**: 658-61.  
803